rheumatology
Rheumatoid arthritis

Five minutes with Prof Roy Fleischmann on the JAK inhibitors

After more than five years of clinical experience with the oral JAK inhibitors, what does the evidence tell us about their safety and efficacy in RA? International expert Professor Roy Fleischmann, a plenary speaker at ARA 2018 in Melbourne, spoke to Michael Woodhead. Are there differences in efficacy the different JAK inhibitors? Clinical trial results ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic